Research
Energy balance
A higher percentage of participants treated with semaglutide lost at least 5% of baseline body weight compared to placebo (86.6% vs 47.6%).
Semaglutide significantly increases the likelihood of achieving clinically meaningful weight loss.
StrongSupportsmedium confidence
More participants treated with semaglutide vs placebo lost at least 5% of baseline body weight (86.6% vs 47.6%, respectively; P < .001).
Why this rating
Based on a randomized, double-blind, parallel-group, phase 3a study design.
Source
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
Thomas A. Wadden et al. · JAMA · 2021
rct · n=611Cited 983×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →